Quebec, Canada – January 31, 2024 – Corealis Pharma, a provider of formulation development and clinical supplies manufacturing of oral solid dosage (OSD) forms has announced the $10 million expansion of its facility in ‘Biotech City,’ a scientific park situated in Laval, Quebec, Canada, increasing its footprint from 30,000 to 45,000 sq ft.
As demand for OSD formulation manufacturing services continues to grow, driven by the need for new therapies and the complexity of new drug molecules, the facility expansion will enable Corealis to continue to seamlessly deliver the level of services its customers have come to expect, while boosting capacity to take on additional business too.
Work is underway to create new formulation development and analytical laboratories in the new facility with this stage of the project slated for completion in April 2024.
In the next expansion stage, available space facilitated by the build-out will be converted into additional GMP manufacturing, packaging, and warehousing capacity and is expected to be completed in Q1 of 2025.
Plans for phase stage 3 are underway.
Corealis is also increasing head count through the expansion of its business development and operational teams as it looks to
secure US market growth in 2024, appointing three new team members who join the Business Development and Sales Department.
Yves Roy, President, Corealis Pharma said: “Our focus for 2024 is firmly on carefully controlled business growth as we ramp up capacity to help more OSD drug developers bring their drug to market.”
“We have a reputation for delivering personalised services with fast project start-up and on-time delivery and we are committed to continuing to deliver this level of service as our business grows and we take on new customers.
“Our expansion plans, alongside our new hires, means we are well placed to support the market as future demand for our services looks promising.”
Corealis Pharma provides OSD pre-formulation, formulation and analytical services. Its clinical supply services include manufacturing and packaging; release and stability; tech transfer and dossier support; quality systems and qualifications.
Contact Corealis
Corealis’ experts are ready to answer any queries about the company’s oral solid dose offering, including its development and manufacturing capabilities.
